ストックスクリーナーアプリを入手
40.95
2.80%
-1.18
アフターアワーズ：
40.47
-0.48
-1.17%
前日終値:
$42.13
開ける：
$42.335
24時間の取引高:
4.52M
Relative Volume:
2.13
時価総額：
$3.78B
収益：
$490.73M
当期純損益:
$-50.26M
株価収益率:
-67.91
EPS:
-0.603
ネットキャッシュフロー:
$-20.37M
1週間 パフォーマンス:
+29.26%
1か月 パフォーマンス:
+47.30%
6か月 パフォーマンス:
+52.51%
1年 パフォーマンス:
+174.65%
1日の値動き範囲:
$40.40
$42.66
1週間の範囲:
$28.29
$43.31
52週間の値動き範囲:
$13.88
$43.31
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
40.95 | 3.89B | 490.73M | -50.26M | -20.37M | -0.603 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-31 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics sees its composite rating rise to 97 - MSN
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 14, 2026 - BioSpace
Travere Therapeutics TVTX Stock 2026 Outlook: Buy Rating Holds After FDA Approval of FILSPARI for FSGS - International Business Times Australia
Travere Therapeutics (TVTX) Shares Surge 33% in Trading - GuruFocus
TVTX (NASDAQ) Form 144 shows proposed resale after PRSU vesting, brokered by Morgan Stanley - Stock Titan
TVTX (NASDAQ: TVTX) files Form 144 to resell 7,215 RSU shares - Stock Titan
Elizabeth Reed reports sales of TVTX common stock (NASDAQ: TVTX) in Form 144 - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 lists RSU vesting and planned share sales - Stock Titan
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease - MedCity News
Travere’s Filspari approved for rare kidney disease FSGS - BioWorld News
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Travere Therapeutics (TVTX) Surges 32.5% in Market Performance - GuruFocus
Affiliate proposes sale of 9,052 TVTX shares via Morgan Stanley (TVTX) - Stock Titan
37,500-share planned sale at TVTX (NASDAQ: TVTX) — insider notice - Stock Titan
Travere Therapeutics Stock Skyrockets On Highly Anticipated FDA Approval - Investor's Business Daily
32,750-share Option Exercise Filed by TVTX (NASDAQ: TVTX) - Stock Titan
Stifel raises Travere Therapeutics price target on Filspari approval - Investing.com
Stifel raises Travere Therapeutics price target on Filspari approval By Investing.com - Investing.com Australia
Sandra Calvin insider sale reported (NASDAQ: TVTX) — 4,333 shares sold - Stock Titan
TVTX Maintained by Citigroup -- Price Target Raised to $53.00 - GuruFocus
Travere Therapeutics (TVTX) Sees 43% Surge After FDA Approval - GuruFocus
FDA approves Filspari for FSGS, Travere’s second indication By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 42.2 USD By Investing.com - Investing.com Australia
TVTX Maintains Rating by Wedbush -- Price Target Raised to $44 - GuruFocus
TVTX Maintained by Canaccord Genuity -- Price Target Raised to $56 - GuruFocus
TVTX Stock Jumps As FDA Approval Fuels Bullish Momentum - StocksToTrade
Ligand (LGND) Partners with Travere on FDA Approval for Filspari - GuruFocus
Travere wins long-awaited approval for kidney disease drug - BioPharma Dive
Travere Therapeutics (TVTX) Stock Rockets 44% on Groundbreaking FSGS Treatment Approval - MEXC
TVTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $47 - GuruFocus
TVTX Stock Jumps As FILSPARI Wins Full FDA Approval - timothysykes.com
Travere Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
TVTX Maintained by Guggenheim -- Price Target Raised to $54.00 - GuruFocus
HC Wainwright Reiterates Buy Rating for Travere Therapeutics - National Today
Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday - Benzinga
Travere Therapeutics stock hits 52-week high at 42.2 USD - Investing.com
Travere Therapeutics Stock Soars 33% After FDA Approves FILSPARI as First Drug for Rare Kidney Disease FSGS - International Business Times Australia
Travere’s Filspari wins landmark US approval - The Pharma Letter
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Wedbush Raises Price Target on Travere Therapeutics to $44 From $39, Keeps Outperform Rating - marketscreener.com
Cantor Fitzgerald reiterates Travere stock rating on FSGS approval By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Stock Surges 44% After FDA Approves FILSPARI for Rare Kidney Disease - CoinCentral
Travere, Ligand win FDA label expansion for Filspari (TVTX) - Seeking Alpha
First approved FSGS drug gives Ligand a 9% sales royalty - Stock Titan
Travere Wins FDA Approval for FILSPARI in FSGS - TipRanks
FDA approves Travere Therapeutics’ Filspairi for expanded kidney disease use - Investing.com
FDA approves FILSPARI for FSGS in Travere (NASDAQ: TVTX) patients - Stock Titan
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):